Literature DB >> 9295168

Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms.

M A Mena1, M J Casarejos, A Carazo, C L Paíno, J García de Yébenes.   

Abstract

Mesencephalic glia produce soluble factors that protect dopamine neurons from L-DOPA toxicity. The chemical composition of these soluble factors is unknown. We investigated the protective effect against L-DOPA neurotoxicity in midbrain dopamine neurons of fractions of different molecular size of glia conditioned medium and candidate neuroprotective agents produced by glia including neurotrophic factors and antioxidants. Protective effects were evaluated according to the number of tyrosine hydroxylase immunoreactive cells, high affinity dopamine uptake and levels of quinones. Both fractions of glia conditioned medium, smaller and larger than 10kD, protected against L-DOPA, but the fraction of smaller molecular size, that contains small free radical scanvenger molecules, was more effective than the fraction of larger molecular size, that contains large neurotrophic peptides. Among the neurotrophic factors GDNF and BDNF totally prevented L-DOPA neurotoxicity, while NGF and bFGF were less effective. However, only NGF significantly reduced the elevation of quinones induced by L-DOPA. Ascorbic acid, at the concentration found in glia conditioned medium, provided partial protective effect against L-DOPA toxicity. Glutathione, had neurotrophic effects on untreated midbrain dopamine neurons and prevented the effect of L-DOPA. In conclusion, the protective effect against L-DOPA neurotoxicity by glia conditioned medium is mediated by several compounds including neurotrophic factors and small antioxidants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295168     DOI: 10.1007/BF01277654

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  41 in total

1.  Measurement of total plasma and cerebrospinal fluid homocysteine by fluorescence following high-performance liquid chromatography and precolumn derivatization with o-phthaldialdehyde.

Authors:  K Hyland; T Bottiglieri
Journal:  J Chromatogr       Date:  1992-08-07

2.  pH-dpendent fluorescence of DNA and RNA in cytologic staining with "33258" Hoeschst.

Authors:  I Hilwig; A Gropp
Journal:  Exp Cell Res       Date:  1975-03-15       Impact factor: 3.905

3.  Long-term follow-up of early dopa treatment in Parkinson's disease.

Authors:  C H Markham; S G Diamond
Journal:  Ann Neurol       Date:  1986-04       Impact factor: 10.422

4.  Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.

Authors:  D M Yurek; K Steece-Collier; T J Collier; J R Sladek
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

5.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.

Authors:  B Pardo; M A Mena; M J Casarejos; C L Paíno; J G De Yébenes
Journal:  Brain Res       Date:  1995-06-05       Impact factor: 3.252

6.  Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.

Authors:  J Sian; D T Dexter; A J Lees; S Daniel; Y Agid; F Javoy-Agid; P Jenner; C D Marsden
Journal:  Ann Neurol       Date:  1994-09       Impact factor: 10.422

7.  Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development.

Authors:  Q Y Zhou; C J Quaife; R D Palmiter
Journal:  Nature       Date:  1995-04-13       Impact factor: 49.962

8.  Glutathione peroxidase, glial cells and Parkinson's disease.

Authors:  P Damier; E C Hirsch; P Zhang; Y Agid; F Javoy-Agid
Journal:  Neuroscience       Date:  1993-01       Impact factor: 3.590

9.  Toxic and protective effects of L-dopa on mesencephalic cell cultures.

Authors:  C Mytilineou; S K Han; G Cohen
Journal:  J Neurochem       Date:  1993-10       Impact factor: 5.372

10.  Oligodendrocyte-type-2 astrocyte (O-2A) progenitors increase the survival of rat mesencephalic, dopaminergic neurons from death induced by serum deprivation.

Authors:  T Takeshima; J M Johnston; J W Commissiong
Journal:  Neurosci Lett       Date:  1994-01-31       Impact factor: 3.046

View more
  10 in total

1.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.

Authors:  G Gille; K Radad; H Reichmann; W-D Rausch
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Optimising levodopa therapy for the management of Parkinson's disease.

Authors:  Fabrizio Stocchi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 5.  Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function.

Authors:  Augusta Pisanu; Laura Boi; Giovanna Mulas; Saturnino Spiga; Sandro Fenu; Anna R Carta
Journal:  J Neural Transm (Vienna)       Date:  2018-03-14       Impact factor: 3.575

Review 6.  The role of astroglia on the survival of dopamine neurons.

Authors:  María Angeles Mena; Sonsoles de Bernardo; Maria José Casarejos; Santiago Canals; Eulalia Rodríguez-Martín
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

Review 7.  Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Authors:  Werner Poewe; Angelo Antonini; Jan Cm Zijlmans; Pierre R Burkhard; François Vingerhoets
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

8.  Protection by glia-conditioned medium in a cell model of Huntington disease.

Authors:  Carolina Ruiz; Maria Jose Casarejos; Ana Gomez; Rosa Solano; Justo Garcia de Yebenes; Maria Angeles Mena
Journal:  PLoS Curr       Date:  2012-07-02

9.  Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice.

Authors:  Juan Perucho; Maria José Casarejos; Ana Gómez; Carolina Ruíz; Maria Ángeles Fernández-Estevez; Maria Paz Muñoz; Justo García de Yébenes; Maria Ángeles Mena
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

Review 10.  Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist.

Authors:  Jinglin Zhang; Louis Chew-Seng Tan
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.